cancer therapeutics

Explore how a closed and integrated instrument workflow takes CAR T cell manufacturing to the next level.

In this webinar, David Bunka will discuss how scientists can use Optimer® binders in cancer research. 

By understanding metabolic reprogramming in cancer, researchers can develop critical therapies.

Discover the benefits of VHH antibody-based therapies.

Researchers assessed the binding affinities of PROTAC binary and ternary complexes with Spectral Shift technology.

Editing epitopes expressed on the surfaces of transplanted hematopoietic stem cells renders them resistant to AML treatments without affecting their critical functions.

In this webinar, Chris Ashdown will discuss how low-intensity vibration affects T cells and how this mechanical stimulation could improve CAR T cell therapy.  

Researchers investigated how cancer antigenicity drives unique forms of T cell exhaustion and hypofunctionality.

Learn about the tumor microenvironment (TME), a key influencer of cancer growth, spread, and treatment success.

From early target discovery to preclinical development stages, researchers explore novel strategies for effective cell therapies in cancer treatment.

Colonizing tumors with engineered bacteria may allow researchers to target sites currently inaccessible to radionuclide therapy.

Scientists isolate rare yet desirable CAR T cell subtypes using an innovative cell sorter system within a closed manufacturing process.

The extent to which transcription is higher in tumor cells than in surrounding nontumor cells is associated with bad prognoses in several cancer types.

Most differences in gene expression among cells within a tumor are likely due to environment or noise, a study suggests. 

A study finds that engineered exosomes are effective in mice, but their potential use in humans raises safety questions.  

A study reveals a molecular pathway linking exercise to an amped-up immune response to pancreatic cancer and greater responsiveness to treatment.

Self-inflicted DNA breaks let the cells hit pause on repair of radiation-induced DNA damage, giving them time to recover, an in vitro study shows.

Because most people are vaccinated against tetanus as children, delivering benign bacteria carrying a tetanus antigen into pancreatic tumors makes them visible to memory cells in the immune system, researchers report.

Unsatisfied by how treatments for childhood leukemia failed to prevent the disease’s return, Pinkel combined them all—and virtually cured the disease.